Comparative Pharmacology
Head-to-head clinical analysis: GLUMETZA versus QTERNMET XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUMETZA versus QTERNMET XR.
GLUMETZA vs QTERNMET XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin hydrochloride, a biguanide, improves glucose tolerance in type 2 diabetes mellitus by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity (increasing peripheral glucose uptake and utilization).
Qternmet XR is a combination of saxagliptin (a DPP-4 inhibitor) and metformin (a biguanide). Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, enhancing glucose-dependent insulin secretion and suppressing glucagon release. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Initial: 500 mg orally once daily with evening meal; increase by 500 mg weekly based on tolerability. Maximum: 2000 mg once daily with evening meal. Extended-release formulation.
Adults: 500 mg orally once daily with the evening meal, increase by 500 mg every 1-2 weeks up to a maximum of 2000 mg once daily. For extended-release (XR) formulation, titrate from 500 mg to 2000 mg once daily.
None Documented
None Documented
6.2 hours (terminal) in healthy adults; prolonged in renal impairment (e.g., 18 hours in CrCl <30 mL/min)
Terminal half-life: 4–6 hours; clinically relevant for dosing interval (every 6–8 hours) and steady-state achievement within 24 hours.
Renal (90% as unchanged drug); fecal (minor, <5%)
Renal: 90% unchanged via glomerular filtration and tubular secretion; fecal: 10%.
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic